Actively Recruiting
Long-term Observational Study in Children Aged 2.5 to Under 17 Years with Hypochondroplasia to Understand Growth and Health Outcomes
Led by QED Therapeutics, a BridgeBio company · Updated on 2026-07-16
150
Participants Needed
25
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are conducting a long-term, multicenter observational study of children aged 2.5 to under 17 years diagnosed with hypochondroplasia HCH. The study aims to evaluate participants growth, medical complications related to HCH, quality of life, functional abilities, and cognitive functions, contributing to a better understanding of the natural history of this condition. No medications or treatments will be given during the study. Participants will not receive any study medication as this is a non-interventional study. The study will collect data over up to 3 years, including annualized height velocity and changes in body proportions such as arm and leg ratios. Medical events and surgical procedures related to HCH will be recorded, along with assessments of cognitive function and physical functioning using standardized questionnaires. Throughout the study, participants and their caregivers will attend study visits to provide data and complete assessments. Evaluations include monitoring growth changes, documenting medical history, and collecting information on quality of life and cognitive abilities. All data collected will help characterize HCH in children better. The total study duration for each participant may be up to 3 years, with ongoing follow-up and monitoring during this time.
CONDITIONS
Brief Title
Prospective Clinical Assessment Study in Children With Hypochondroplasia
Research Team
Q
QED Therapeutics, Inc
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here